ClinicalTrials.gg
CompletedNCT02970968Updated Aug 6, 2024Results posted

Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of Gastroparesis

A Phase 2 interventional study of VLY-686 (Tradipitant) and Placebo in Gastroparesis, sponsored by Vanda Pharmaceuticals. Completed at 38 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-08-06.

Sponsored by Vanda Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
152
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 184 studies in Gastroparesis with a site in United States — 33 open to participants now, 41 under way, 2 of them phase 3. Gastroparesis · United States.

Enrollment
25th of 136
152 · median 36
Started
2016
with 3 others
Phase 2
38 of 184
none open now
Registered
76th of 184
by date

Among the 184 studies in Gastroparesis with a site in United States, this one is the 25th largest by enrollment of the 136 interventional ones that give a count, is one of 4 that started in 2016, is one of 38 in phase 2, and was the 76th registered.

Gastroparesis

323 studies on the registry are indexed under Gastroparesis; 75 are open to participants now.

Browse Gastroparesis studies →

Open to participants now

33 of the 184 studies in Gastroparesis with a site in United States are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 49 Gastroparesis studies recruiting now, 25 (51%) set no upper age limit and 14 (29%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 184 studies in Gastroparesis with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States. One hundred fifty (150) subjects diagnosed with gastroparesis, who satisfy the selection criteria for the study, will be randomized to one of two treatment groups, active or placebo.

Read the detailed description

This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States. One hundred fifty (150) subjects diagnosed with gastroparesis, who satisfy the selection criteria for the study, will be randomized to one of two treatment groups, active or placebo.

The study is divided into two phases: the screening phase and the evaluation phase. The screening phase includes a screening visit to evaluate subjects' preliminary eligibility for the study. During the screening phase, subjects will collect diary data for at least 4 weeks. The evaluation phase includes 4 weeks of randomized double-blind treatment.

03

Conditions studied

  • Gastroparesis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosed with gastroparesis;
  2. Subjects must agree to the use of
  3. Ability and acceptance to provide written ;
  4. Willing to participate in the pharmacogenomics sample collection;
  5. Willing and able to comply with all study requirements and restrictions
  6. Willing to not participate in any other interventional trial for the duration of their participation.

Exclusion criteria

Exclusion Criteria:

  1. Another active disorder or treatment which could explain or contribute to symptoms in the opinion of the Investigator (including but not limited to gastric , neurological disorder, or heavy doses of strong anticholinergics);
  2. Pregnancy or nursing;
  3. History of intolerance and/or to medications similar to VLY-686 (Tradipitant) and its accompanying ;
  4. Use of another NK1 antagonist or palonosetron;
  5. Exposure to any medication, including placebo, within 60 days of the Baseline Visit;
  6. Any other reason as determined by the Investigator which may lead to an unfavorable risk-benefit of study participation, may interfere with study compliance, or may confound study results.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
152 participants (actual)

Study arms

  • Experimental
    Study Drug

    VLY-686 (Tradipitant) oral capsule for 4 weeks.

    Drug: VLY-686 (Tradipitant)

  • Placebo comparator
    Placebo

    Placebo oral capsule for 4 weeks.

    Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Average Nausea Severity

    The Gastroparesis Core Symptom Daily Diary (GCSDD) is a patient reported diary that asks patients to rate the worst occurrence of each cardinal symptom of gastroparesis (nausea severity, early satiety, postprandial fullness, bloating, and abdominal pain) in the past 24 hours on a Likert scale from 0 (no symptoms) to 5 (very severe). Change from baseline in average nausea severity score is calculated as the weekly average post value minus baseline value of the daily nausea severity score from the GCSDD. A negative change indicates improvement.

    Time frame: 4 weeks

Secondary outcomes

  1. Weekly % Nausea-Free Days

    The Gastroparesis Core Symptom Daily Diary (GCSDD) is a patient reported diary that asks patients if they have had any nausea over the past 24 hours and if yes, to rate the worst occurrence in the past 24 hours on a Likert scale from 1 (very mild) to 5 (very severe). Change in weekly percentage of nausea-free days from baseline is calculated as weekly average post value minus baseline value. Baseline is defined as the average of all nonmissing values in the screening phase (4 weeks).

    Time frame: 4 weeks

  2. Daily Average Vomiting Frequency, Change From Baseline

    The Gastroparesis Core Symptom Daily Diary (GCSDD) is a patient reported diary that asks patients if they have vomited in the past 24 hours and how many times they vomited in the past 24 hours. Change from baseline in the weekly average of daily vomiting frequency is calculated as the weekly average post value minus baseline value of the daily daily vomiting frequency from the GCSDD. Baseline is defined as the average of all non-missing values in the screening phase (4 weeks). A negative change indicates improvement.

    Time frame: 4 weeks

  3. Gastroparesis Cardinal Symptom Index (GCSI), Change From Baseline

    The GCSI is a subject reported outcome administered in-clinic with a 2-week recall period to measure the severity of symptoms in gastroparesis. The GCSI is composed of 9 items based on three subscales: post-prandial fullness/early satiety (4 items); nausea/vomiting (3 items), and bloating (2 items). The severity of each symptom is rated on a six-point Likert response scale. The minimal scale value = 0 (none) and the maximum scale value = 5 (very severe). GCSI Total score is constructed as the average of the three symptom sub-scales. Higher score is indicative of greater symptom severity.

    Time frame: 4 weeks

  4. PAGI-SYM, Change From Baseline

    The PAGI-SYM is a patient reported outcome which asks patients to describe the severity of their symptoms over the last two weeks to measure symptom severity for gastroparesis, functional dyspepsia, and gastroesophageal reflux disease. The measure consists of 20 symptom severity items, which cover the following domains: nausea/vomiting, fullness/early satiety, bloating, upper abdominal pain, heartburn/regurgitation, and lower abdominal pain. This questionnaire includes the Gastroparesis Cardinal Symptom Index (GCSI). The severity of each symptom is rated on a six-point Likert response scale. The minimal scale value = 0 (none) and the maximum scale value= 5 (very severe). PAGI-SYM Total score is constructed as the average of the six symptom sub-scales and a higher score is indicative of greater symptom severity.

    Time frame: 4 weeks

  5. CGI-S, Change From Baseline

    The Clinician Global Impression of Severity (CGI-S) is a 7-point scale on which the clinician rates the severity of the patient's gastroparesis at the time of the assessment and refers to the degree of illness at the time of the visit and during the 2 weeks before the visit. The CGI-S is rated on the following 7-point scale: 1: normal, not at all ill; 2: borderline ill: 3: mildly ill; 4: moderately ill; 5: markedly ill; 6: severely ill; 7: among the most extremely ill patients. Change from baseline is calculated as post value minus baseline value. A negative change indicates improvement.

    Time frame: 4 weeks

  6. PGI-C

    The Patient Global Impression of Change (PGI-C) is a patient reported questionnaire with a 7-point rating scale where the participant rates his/her own improvement in overall symptoms relative to the baseline assessment. Is is rated as 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. Higher scores indicate a worse outcome.

    Time frame: 4 weeks

07

Results

Posted Aug 6, 2024
Limitations and caveats
Studies are needed to determine the mechanisms by which tradipitant reduces nausea and vomiting, and powered to assess idiopathic and diabetic gastroparesis separately.

Participant flow

Participant flow — Overall Study
MilestoneTradipitantPlacebo
Started7775
Completed7268
Not completed57
Withdrew: Withdrawal by subject33
Withdrew: Adverse event12
Withdrew: Lost to follow-up11
Withdrew: Non-compliance01

Outcome measures

PrimaryChange From Baseline in Average Nausea Severity

The Gastroparesis Core Symptom Daily Diary (GCSDD) is a patient reported diary that asks patients to rate the worst occurrence of each cardinal symptom of gastroparesis (nausea severity, early satiety, postprandial fullness, bloating, and abdominal pain) in the past 24 hours on a Likert scale from 0 (no symptoms) to 5 (very severe). Change from baseline in average nausea severity score is calculated as the weekly average post value minus baseline value of the daily nausea severity score from the GCSDD. A negative change indicates improvement.

Time frame:
4 weeks
Reported as:
Least squares mean · score on a scale (change from baseline)
Change From Baseline in Average Nausea Severity
score on a scale (change from baseline)TradipitantPlacebo
Change From Baseline in Average Nausea Severity-1.25 (-1.53 to -0.98)-0.73 (-1.02 to -0.44)
Statistical analysis
  • Tradipitant vs Placebo · Mixed Models Analysis · p = .0099
SecondaryWeekly % Nausea-Free Days

The Gastroparesis Core Symptom Daily Diary (GCSDD) is a patient reported diary that asks patients if they have had any nausea over the past 24 hours and if yes, to rate the worst occurrence in the past 24 hours on a Likert scale from 1 (very mild) to 5 (very severe). Change in weekly percentage of nausea-free days from baseline is calculated as weekly average post value minus baseline value. Baseline is defined as the average of all nonmissing values in the screening phase (4 weeks).

Time frame:
4 weeks
Reported as:
Least squares mean · Percentage (%) of nausea-free days
Weekly % Nausea-Free Days
Percentage (%) of nausea-free daysTradipitantPlacebo
Weekly % Nausea-Free Days28.81 (21.09 to 36.53)15.00 (6.94 to 23.07)
Statistical analysis
  • Tradipitant vs Placebo · Mixed Models Analysis · p = .0160
SecondaryDaily Average Vomiting Frequency, Change From Baseline

The Gastroparesis Core Symptom Daily Diary (GCSDD) is a patient reported diary that asks patients if they have vomited in the past 24 hours and how many times they vomited in the past 24 hours. Change from baseline in the weekly average of daily vomiting frequency is calculated as the weekly average post value minus baseline value of the daily daily vomiting frequency from the GCSDD. Baseline is defined as the average of all non-missing values in the screening phase (4 weeks). A negative change indicates improvement.

Time frame:
4 weeks
Reported as:
Least squares mean · weekly average of daily vomit episodes
Daily Average Vomiting Frequency, Change From Baseline
weekly average of daily vomit episodesTradipitantPlacebo
Daily Average Vomiting Frequency, Change From Baseline-0.49 (-0.64 to -0.34)-0.26 (-0.42 to -0.10)
Statistical analysis
  • Tradipitant vs Placebo · Mixed Models Analysis · p = .039
SecondaryGastroparesis Cardinal Symptom Index (GCSI), Change From Baseline

The GCSI is a subject reported outcome administered in-clinic with a 2-week recall period to measure the severity of symptoms in gastroparesis. The GCSI is composed of 9 items based on three subscales: post-prandial fullness/early satiety (4 items); nausea/vomiting (3 items), and bloating (2 items). The severity of each symptom is rated on a six-point Likert response scale. The minimal scale value = 0 (none) and the maximum scale value = 5 (very severe). GCSI Total score is constructed as the average of the three symptom sub-scales. Higher score is indicative of greater symptom severity.

Time frame:
4 weeks
Reported as:
Least squares mean · score on a scale (change from baseline)
Gastroparesis Cardinal Symptom Index (GCSI), Change From Baseline
score on a scale (change from baseline)TradipitantPlacebo
Gastroparesis Cardinal Symptom Index (GCSI), Change From Baseline-0.93 (-1.14 to -0.73)-0.58 (-0.80 to -0.36)
Statistical analysis
  • Tradipitant vs Placebo · Mixed Models Analysis · p = .0223
SecondaryPAGI-SYM, Change From Baseline

The PAGI-SYM is a patient reported outcome which asks patients to describe the severity of their symptoms over the last two weeks to measure symptom severity for gastroparesis, functional dyspepsia, and gastroesophageal reflux disease. The measure consists of 20 symptom severity items, which cover the following domains: nausea/vomiting, fullness/early satiety, bloating, upper abdominal pain, heartburn/regurgitation, and lower abdominal pain. This questionnaire includes the Gastroparesis Cardinal Symptom Index (GCSI). The severity of each symptom is rated on a six-point Likert response scale. The minimal scale value = 0 (none) and the maximum scale value= 5 (very severe). PAGI-SYM Total score is constructed as the average of the six symptom sub-scales and a higher score is indicative of greater symptom severity.

Time frame:
4 weeks
Reported as:
Least squares mean · score on a scale (change from baseline)
PAGI-SYM, Change From Baseline
score on a scale (change from baseline)TradipitantPlacebo
PAGI-SYM, Change From Baseline-0.93 (-1.12 to -0.74)-0.65 (-0.86 to -0.45)
Statistical analysis
  • Tradipitant vs Placebo · Mixed Models Analysis · p = .0497
SecondaryCGI-S, Change From Baseline

The Clinician Global Impression of Severity (CGI-S) is a 7-point scale on which the clinician rates the severity of the patient's gastroparesis at the time of the assessment and refers to the degree of illness at the time of the visit and during the 2 weeks before the visit. The CGI-S is rated on the following 7-point scale: 1: normal, not at all ill; 2: borderline ill: 3: mildly ill; 4: moderately ill; 5: markedly ill; 6: severely ill; 7: among the most extremely ill patients. Change from baseline is calculated as post value minus baseline value. A negative change indicates improvement.

Time frame:
4 weeks
Reported as:
Least squares mean · score on a scale (change from baseline)
CGI-S, Change From Baseline
score on a scale (change from baseline)TradipitantPlacebo
CGI-S, Change From Baseline-1.13 (-1.36 to -0.91)-0.74 (-0.98 to -0.50)
Statistical analysis
  • Tradipitant vs Placebo · Mixed Models Analysis · p = .0207
SecondaryPGI-C

The Patient Global Impression of Change (PGI-C) is a patient reported questionnaire with a 7-point rating scale where the participant rates his/her own improvement in overall symptoms relative to the baseline assessment. Is is rated as 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. Higher scores indicate a worse outcome.

Time frame:
4 weeks
Reported as:
Least squares mean · score on a scale (change from baseline)
PGI-C
score on a scale (change from baseline)TradipitantPlacebo
PGI-C2.66 (2.40 to 2.93)3.06 (2.78 to 3.35)
Statistical analysis
  • Tradipitant vs Placebo · Mixed Models Analysis · p = .0429
Post-hocChange From Baseline in Average Nausea Severity; Baseline Vomiting Group

The Gastroparesis Core Symptom Daily Diary (GCSDD) is a patient reported diary that asks patients to rate the worst occurrence of each cardinal symptom of gastroparesis (nausea severity, early satiety, postprandial fullness, bloating, and abdominal pain) in the past 24 hours on a Likert scale from 0 (no symptoms) to 5 (very severe). Change from baseline in average nausea severity score is calculated as the weekly average post value minus baseline value of the daily nausea severity score from the GCSDD. A negative change indicates improvement.

Time frame:
4 weeks
Reported as:
Least squares mean · score on a scale (change from baseline)
Change From Baseline in Average Nausea Severity; Baseline Vomiting Group
score on a scale (change from baseline)TradipitantPlacebo
Change From Baseline in Average Nausea Severity; Baseline Vomiting Group-1.43 (-1.72 to -1.14)-0.42 (-0.76 to -0.07)
Statistical analysis
  • Tradipitant vs Placebo · Mixed Models Analysis · p = <.0001
Post-hocGCSDD, % Nausea-Free Days; Baseline Vomiting Group

The Gastroparesis Core Symptom Daily Diary (GCSDD) is a patient reported diary that asks patients to rate the worst occurrence of each cardinal symptom of gastroparesis in the past 24 hours on a scale from 0 (no symptoms) to 5 (very severe).

Time frame:
4 weeks
Reported as:
Least squares mean · Percentage (%) of nausea-free days
GCSDD, % Nausea-Free Days; Baseline Vomiting Group
Percentage (%) of nausea-free daysTradipitantPlacebo
GCSDD, % Nausea-Free Days; Baseline Vomiting Group32.3 (23.8 to 40.8)7.6 (-2.3 to 17.5)
Statistical analysis
  • Tradipitant vs Placebo · Mixed Models Analysis · p = .0003
Post-hocGCSDD, Daily Average Vomiting Frequency, Change From Baseline; Baseline Vomiting Group

The Gastroparesis Core Symptom Daily Diary (GCSDD) is a patient reported diary that asks patients to rate the worst occurrence of each cardinal symptom of gastroparesis in the past 24 hours on a scale from 0 (no symptoms) to 5 (very severe). Change from baseline is calculated as post value minus baseline value. A negative change indicates improvement.

Time frame:
4 weeks
Reported as:
Least squares mean · weekly average of daily vomit episodes
GCSDD, Daily Average Vomiting Frequency, Change From Baseline; Baseline Vomiting Group
weekly average of daily vomit episodesTradipitantPlacebo
GCSDD, Daily Average Vomiting Frequency, Change From Baseline; Baseline Vomiting Group-0.69 (-0.89 to -0.49)-0.32 (-0.56 to -0.08)
Statistical analysis
  • Tradipitant vs Placebo · Mixed Models Analysis · p = .023
Post-hocGastroparesis Cardinal Symptom Index (GCSI), Change From Baseline; Baseline Vomiting Group

The GCSI is a subject reported outcome administered in-clinic with a 2-week recall period to measure the severity of symptoms in gastroparesis. The GCSI is composed of 9 items based on three subscales: post-prandial fullness/early satiety (4 items); nausea/vomiting (3 items), and bloating (2 items). The severity of each symptom is rated on a six-point Likert response scale. The minimal scale value = 0 (none) and the maximum scale value = 5 (very severe). GCSI Total score is constructed as the average of the three symptom sub-scales. Higher score is indicative of greater symptom severity.

Time frame:
4 weeks
Reported as:
Least squares mean · score on a scale (change from baseline)
Gastroparesis Cardinal Symptom Index (GCSI), Change From Baseline; Baseline Vomiting Group
score on a scale (change from baseline)TradipitantPlacebo
Gastroparesis Cardinal Symptom Index (GCSI), Change From Baseline; Baseline Vomiting Group-1.10 (-1.33 to -0.87)-0.60 (-0.88 to -0.32)
Statistical analysis
  • Tradipitant vs Placebo · Mixed Models Analysis · p = .0078
Post-hocPAGI-SYM, Change From Baseline; Baseline Vomiting Group

The PAGI-SYM is a patient reported outcome which asks patients to describe the severity of their symptoms over the last two weeks to measure symptom severity for gastroparesis, functional dyspepsia, and gastroesophageal reflux disease. The measure consists of 20 symptom severity items, which cover the following domains: nausea/vomiting, fullness/early satiety, bloating, upper abdominal pain, heartburn/regurgitation, and lower abdominal pain. This questionnaire includes the Gastroparesis Cardinal Symptom Index (GCSI). The severity of each symptom is rated on a six-point Likert response scale. The minimal scale value = 0 (none) and the maximum scale value= 5 (very severe). PAGI-SYM Total score is constructed as the average of the six symptom sub-scales and a higher score is indicative of greater symptom severity.

Time frame:
4 weeks
Reported as:
Least squares mean · score on a scale (change from baseline)
PAGI-SYM, Change From Baseline; Baseline Vomiting Group
score on a scale (change from baseline)TradipitantPlacebo
PAGI-SYM, Change From Baseline; Baseline Vomiting Group-1.06 (-1.28 to -0.85)-0.69 (-0.95 to -0.43)
Statistical analysis
  • Tradipitant vs Placebo · Mixed Models Analysis · p = .0294
Post-hocCGI-S, Change From Baseline; Baseline Vomiting Group

The Clinician Global Impression of Severity (CGI-S) is a 7-point scale on which the clinician rates the severity of the patient's gastroparesis at the time of the assessment and refers to the degree of illness at the time of the visit and during the 2 weeks before the visit. The CGI-S is rates on the following 7-point scale: 1: normal, not at all ill; 2: borderline ill: 3: mildly ill; 4: moderately ill; 5: markedly ill; 6: severely ill; 7: among the most extremely ill patients. Change from baseline is calculated as post value minus baseline value. A negative change indicates improvement.

Time frame:
4 weeks
Reported as:
Least squares mean · score on a scale (change from baseline)
CGI-S, Change From Baseline; Baseline Vomiting Group
score on a scale (change from baseline)TradipitantPlacebo
CGI-S, Change From Baseline; Baseline Vomiting Group-1.24 (-1.49 to -0.99)-0.79 (-1.08 to -0.49)
Statistical analysis
  • Tradipitant vs Placebo · Mixed Models Analysis · p = .0229
Post-hocPGI-C; Baseline Vomiting Group

The Patient Global Impression of Change (PGI-C) is a patient reported questionnaire with a 7-point rating scale where the participant rates his/her own improvement in overall symptoms relative to the baseline assessment. Is is rated as 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. Higher scores indicate a worse outcome.

Time frame:
4 weeks
Reported as:
Least squares mean · score on a scale (change from baseline)
PGI-C; Baseline Vomiting Group
score on a scale (change from baseline)TradipitantPlacebo
PGI-C; Baseline Vomiting Group2.52 (2.24 to 2.81)3.24 (2.90 to 3.59)
Statistical analysis
  • Tradipitant vs Placebo · Mixed Models Analysis · p = .0018
Post-hocNausea Responder Rate (%)

Defined as a nausea score of very mild or better (≤1) in average daily nausea severity at week 4. Nausea severity is rated on a Likert scale from 0 (none) to 5 (very severe).

Time frame:
4 weeks
Reported as:
Number · Percentage (%) of nausea responders
Nausea Responder Rate (%)
Percentage (%) of nausea respondersTradipitantPlacebo
Nausea Responder Rate (%)32.911.8
Statistical analysis
  • Tradipitant vs Placebo · Mixed Models Analysis · p = .0013
Post-hocNausea Responder Rate (%); Baseline Vomiting Group

Defined as a nausea score of very mild or better (≤1) in average daily nausea severity at week 4. Nausea severity is rated on a Likert scale from 0 (none) to 5 (very severe).

Time frame:
4 weeks
Reported as:
Number · Percentage (%) of nausea responders
Nausea Responder Rate (%); Baseline Vomiting Group
Percentage (%) of nausea respondersTradipitantPlacebo
Nausea Responder Rate (%); Baseline Vomiting Group36.26.9
Statistical analysis
  • Tradipitant vs Placebo · Mixed Models Analysis · p = .0001
Post-hocComplete Nausea Responder Rate (%)

Defined as a nausea score of 0 in at week 4. Nausea severity is rated on a Likert scale from 0 (none) to 5 (very severe).

Time frame:
4 weeks
Reported as:
Number · Percentage (%) of participants
Complete Nausea Responder Rate (%)
Percentage (%) of participantsTradipitantPlacebo
Complete Nausea Responder Rate (%)15.074.4
Statistical analysis
  • Tradipitant vs Placebo · Mixed Models Analysis · p = .018
Post-hocComplete Nausea Responder Rate (%); Baseline Vomiting Group

Defined as a nausea score of 0 at week 4. Nausea severity is rated on a Likert scale from 0 (none) to 5 (very severe).

Time frame:
4 weeks
Reported as:
Number · Percentage (%) of participants
Complete Nausea Responder Rate (%); Baseline Vomiting Group
Percentage (%) of participantsTradipitantPlacebo
Complete Nausea Responder Rate (%); Baseline Vomiting Group17.244.65
Statistical analysis
  • Tradipitant vs Placebo · Mixed Models Analysis · p = .0164
Post-hocPercentage of Participants With Clinically Meaningful Improvement on Total GCSI Score

Defined as 1-point or greater improvement on their GCSI total score from baseline to week 4. The GCSI is a subject reported outcome. Part I consists of the traditional GCSI and severity rating of upper abdominal pain and severity of overall symptoms on a 0 (none) to 5 (very severe) Likert scale. Part II uses a 7-point rating scale for the subject to rate their own improvement relative to baseline. Symptoms are rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. The GCSI subscale scores, nausea/vomiting (3 items), postprandial fullness/early satiety (4 items), bloating (2 items), and upper abdominal pain (2 items), are calculated by taking the mean of non-missing items in each subscale; the subscale scores vary from 0 (none or absent) to 5 (very severe). The total score is calculated by taking the mean of the three subscales (except upper abdominal pain and overall symptom item).

Time frame:
4 weeks
Reported as:
Number · Percentage (%)
Percentage of Participants With Clinically Meaningful Improvement on Total GCSI Score
Percentage (%)TradipitantPlacebo
Percentage of Participants With Clinically Meaningful Improvement on Total GCSI Score46.623.5
Statistical analysis
  • Tradipitant vs Placebo · Mixed Models Analysis · p = .0053
Post-hocPercentage of Participants With Clinically Meaningful Improvement on Total GCSI Score; Baseline Vomiting Group

Defined as 1-point or greater improvement on their GCSI total score from baseline to week 4. The GCSI is a subject reported outcome. Part I consists of the traditional GCSI and severity rating of upper abdominal pain and severity of overall symptoms on a 0 (none) to 5 (very severe) Likert scale. Part II uses a 7-point rating scale for the subject to rate their own improvement relative to baseline. Symptoms are rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. The GCSI subscale scores, nausea/vomiting (3 items), postprandial fullness/early satiety (4 items), bloating (2 items), and upper abdominal pain (2 items), are calculated by taking the mean of non-missing items in each subscale; the subscale scores vary from 0 (none or absent) to 5 (very severe). The total score is calculated by taking the mean of the three subscales (except upper abdominal pain and overall symptom item).

Time frame:
4 weeks
Reported as:
Number · Percentage (%)
Percentage of Participants With Clinically Meaningful Improvement on Total GCSI Score; Baseline Vomiting Group
Percentage (%)TradipitantPlacebo
Percentage of Participants With Clinically Meaningful Improvement on Total GCSI Score; Baseline Vomiting Group51.723.3
Statistical analysis
  • Tradipitant vs Placebo · Mixed Models Analysis · p = .0020

Adverse events

Collected over 8 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tradipitant0/77 (0%)0/77 (0%)31/77 (40.3%)
Placebo0/75 (0%)1/75 (1.3%)20/75 (26.7%)
Most frequent serious events
Most frequent serious events
EventTradipitantPlacebo
SyncopeNervous system disorders0/771/75
Most frequent other events
Showing 10 of 17
Most frequent other events
EventTradipitantPlacebo
NauseaGastrointestinal disorders2/775/75
DiarrheaGastrointestinal disorders4/773/75
HeadacheNervous system disorders1/773/75
SomnolenceNervous system disorders3/770/75
FatigueGeneral disorders3/771/75
Abdominal painGastrointestinal disorders2/772/75
DizzinessNervous system disorders2/772/75
Abdominal pain upperGastrointestinal disorders2/770/75
Dry mouthGastrointestinal disorders2/770/75
RashSkin and subcutaneous tissue disorders2/770/75

Baseline characteristics

Age, Continuous
Age, Continuous(years)TradipitantPlaceboTotal
Mean45.4 ± 13.1646.4 ± 13.4645.9 ± 13.28
Sex: Female, Male
Sex: Female, Male(Participants)TradipitantPlaceboTotal
Female6968137
Male8715
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TradipitantPlaceboTotal
American Indian or Alaska Native123
Asian112
Native Hawaiian or Other Pacific Islander000
Black or African American9716
White6665131
More than one race000
Unknown or Not Reported000
Disease Etiology
Disease Etiology(Participants)TradipitantPlaceboTotal
Idiopathic464591
Diabetic313061
08

Study locations

38 sites
  • Vanda Investigational Site
    Dothan, Alabama 36305, United States
  • Vanda Investigational Site
    Huntsville, Alabama 35801, United States
  • Vanda Investigational Site
    Tucson, Arizona 85712, United States
  • Vanda Investigational Site
    Little Rock, Arkansas 72211, United States
  • Vanda Investigational Site
    Chula Vista, California 91910, United States
  • Vanda Investigational Site
    Los Angeles, California 90095, United States
  • Vanda Investigational Site
    Palo Alto, California 94305, United States
  • Vanda Investigational Site
    San Francisco, California 94115, United States
  • Vanda Investigational Site
    Jacksonville, Florida 32256, United States
  • Vanda Investigational Site
    Largo, Florida 33777, United States
  • Vanda Investigational Site
    Miami, Florida 33134, United States
  • Vanda Investigational Site
    Athens, Georgia 30607, United States
  • Vanda Investigational Site
    Elgin, Illinois 60123, United States
  • Vanda Investigational Site
    Indianapolis, Indiana 46202, United States
  • Vanda Investigational Site
    Louisville, Kentucky 40202, United States
  • Vanda Investigational Site
    Marrero, Louisiana 70072, United States
  • Vanda Investigational Site
    Chevy Chase, Maryland 20815, United States
  • Vanda Investigational Site
    Boston, Massachusetts 02114, United States
  • Vanda Investigational Site
    Boston, Massachusetts 02215, United States
  • Vanda Investigational Site
    Wyoming, Michigan 49519, United States
  • Vanda Investigational Site
    Minneapolis, Minnesota 55114, United States
  • Vanda Investigational Site
    Pascagoula, Mississippi 39564, United States
  • Vanda Investigational Site
    Saint Louis, Missouri 63104, United States
  • Vanda Investigational Site
    Great Neck, New York 11023, United States
  • Vanda Investigational Site
    New York, New York 10028, United States
  • Vanda Investigational Site
    Raleigh, North Carolina 27612, United States
  • Vanda Investigational Site
    Salisbury, North Carolina 28144, United States
  • Vanda Investigational Site
    Huber Heights, Ohio 45424, United States
  • Vanda Investigational Site
    Mentor, Ohio 44060, United States
  • Vanda Investigational Site
    Tulsa, Oklahoma 74104, United States
  • Vanda Investigational Site
    Philadelphia, Pennsylvania 19140, United States
  • Vanda Investigational Site
    Chattanooga, Tennessee 37421, United States
  • Vanda Investigational Site
    Jackson, Tennessee 38305, United States
  • Vanda Investigational Site
    Nashville, Tennessee 37211, United States
  • Vanda Investigational Site
    El Paso, Texas 79905, United States
  • Vanda Investigational Site
    Houston, Texas 77030, United States
  • Vanda Investigational Site
    Richardson, Texas 75082, United States
  • Vanda Investigational Site
    Norfolk, Virginia 23502, United States
09

References and documents

Publications

  • Carlin JL, Lieberman VR, Dahal A, Keefe MS, Xiao C, Birznieks G, Abell TL, Lembo A, Parkman HP, Polymeropoulos MH. Efficacy and Safety of Tradipitant in Patients With Diabetic and Idiopathic Gastroparesis in a Randomized, Placebo-Controlled Trial. Gastroenterology. 2021 Jan;160(1):76-87.e4. doi: 10.1053/j.gastro.2020.07.029. Epub 2020 Jul 18. PubMed 32693185 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Nov 2018, 24 months.

Results were first posted in Aug 2024, 5 years 9 months after primary completion.

Of 20 phase 2 interventional studies under Gastroparesis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 24 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2016
First posted
Nov 22, 2016
StartActual
Nov 2016
Primary completionActual
Nov 2018
CompletionActual
Dec 2018
Results first posted
Aug 6, 2024
Last update
Aug 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02970968
Responsible party
Sponsor
First posted
Nov 22, 2016
Start date
Nov 2016
Primary completion
Nov 2018
Completion
Dec 2018
Results posted
Aug 6, 2024
Last update
Aug 6, 2024

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tradipitant

Start the discussion